CAPR SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Capricor
Capricor investors lost 60% to 70% after FDA briefing documents raised significant concerns regarding Deramiocel, following earlier Company statements that the FDA had not identified material review issues. NEW YORK, July 30, 2026 /PRNewswire/ -- FDA staff briefing documents released on...
Capricor investors lost 60% to 70% after FDA briefing documents raised significant concerns regarding Deramiocel, following earlier Company statements that the FDA had not identified material review issues. NEW YORK, July 30, 2026 /PRNewswire/ -- FDA staff briefing documents released on...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.